Polymer conjugates for focal and targeted delivery of drugs

Polymers for Advanced Technologies

Volumn 24, Issue 9, 2013, Pages 777-790

  Polyak, Dina ^a   Eldar Boock, Anat ^a   Baabur Cohen, Hemda ^a   Satchi Fainaro, Ronit ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Angiogenesis; Cancer therapeutics; Nanomedicine; Polymer conjugates; Targeted delivery

Indexed keywords

ANGIOGENESIS; CANCER THERAPEUTICS; HIGH MOLECULAR WEIGHT; POLYMER CONJUGATE; POLYMERIC NANOCARRIERS; SUPRAMOLECULAR STRUCTURE; TARGETED DELIVERY; THERAPEUTIC POTENTIALS;

DISEASES; MEDICAL NANOTECHNOLOGY;

FUNCTIONAL POLYMERS;

EID: 84883051086     PISSN: 10427147     EISSN: 10991581     Source Type: Journal    
DOI: 10.1002/pat.3158     Document Type: Article

References (143)

1. H. Ringsdorf, Structure and properties of pharmacologically active polymers. J. Polym. Sci. Symp., 1975. 51, 135-153.
2. H. Baabur-Cohen, L. Omer, and R. Satchi-Fainaro, Recent progress in polymer therapeutics as nanomedicines, in Handbook for Harnessing Biomaterials for Nanomedicine: Preparation, Toxicity and Applications, (Ed. D. Peer ), Pan Stanford publishing: London, UK, 2011.
3. Y. Matsumura, and H. Maeda, A New Concept for Macromolecular Therapeutics in Cancer-Chemotherapy - Mechanism of Tumoritropic Accumulation of Proteins and the Antitumor Agent Smancs. Cancer Res., 1986. 46(12) 6387-6392.
4. H. Maeda, et al., Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release, 2000. 65(1-2): 271-284.
5. Alexis, F., et al., Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm., 2008. 5(4): 505-515.
6. Davis, M.E., The First Targeted Delivery of siRNA in Humans via a Self-Assembling, Cyclodextrin Polymer-Based Nanoparticle: From Concept to Clinic. Mol. Pharm., 2009. 6(3): 659-668.
7. Perrault, S.D., et al., Mediating Tumor Targeting Efficiency of Nanoparticles Through Design. Nano Lett., 2009. 9(5): p. 1909-1915.
8. B. Alberts, B. D., Johnson A., Lewis J., Raff M., K. Roberts, Walter P., Essential Cell Biology. 1998, New York: Garland Publishing. 472-477.
9. R. Satchi-Fainaro, R. Duncan, and C. M. Barnes, Polymer therapeutics for cancer: Current status and future challenges. Polymer Therapeutics Ii: Polymers as Drugs, Conjugates and Gene Delivery Systems, 2006. 193: 1-65.
10. M. Markman, Improving the toxicity profile of chemotherapy for advanced ovarian cancer: a potential role for CT-2103. J. Exp. Ther. Oncol., 2004. 4(2): 131-6.
11. Langer, C. J., CT-2103: a novel macromolecular taxane with potential advantages compared with conventional taxanes. Clin. Lung Cancer, 2004. 6 Suppl 2: S85-8.
12. R. Pawar, et al., A. Polysaccharides as carriers of bioactive agents for medical application. Natural-Based Polymers for Biomedical Applications, ed. R.L.E. Reis . 2008, New York: Woodhead Pub. 50.
13. P. Caliceti, S. Salmaso, and S. Bersani, Polysaccharide-base anticancer prodrugs. Macromolecular Anticancer Therapeutics, ed. P. E. Harivardhan R. L.; Couvreur . 2010, New York: Humana Press. 163-220.
14. S. Danhauser-Riedl, et al., Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD). Invest. New Drugs, 1993. 11(2-3): 187-95.
15. R. S. Singh, G. K. Saini, and J. F. Kennedy, Pullulan: microbial sources, production and applications. Carbohy. Polym., 2008. 73: 515-531.
16. Leather, T. D., Production and applications of pullulan. Appl. Microbiol. Biotechnol., 2003. 62: 468-473.
17. Kim, S., et al., Insulinotropic activity of sulfonylurea/pullulan conjugate in rat islet microcapsule. Biomaterials, 2003. 24(26): 4843-51.
18. Scomparin, A., et al., Novel folated and non-folated pullulan bioconjugates for anticancer drug delivery. Eur. J. Pharm. Sci., 2011. 42(5): 547-58.
19. K. Miller, et al., Self-Assembled Dendritic-PEG Micelles Bearing Paclitaxel and Alendronate for Targeting Breast and Prostate Cancer Bone Metastasis. 2010.
20. J. Kopecek, and P. Kopeckova, HPMA copolymers: origins, early developments, present, and future. Adv. Drug Deliv. Rev., 2010. 62(2): 122-49.
21. P. A. Vasey, et al., Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin Cancer Res, 1999. 5(1): 83-94.
22. Duncan, R., Development of HPMA copolymer-anticancer conjugates: clinical experience and lessons learnt. Adv. Drug Deliv. Rev., 2009. 61(13): 1131-48.
23. Ulbrich, K., et al., Polymeric conjugates of drugs and antibodies for site-specific drug delivery. Macromol. Symp., 1996. 103: 177-192.
24. D. Putnam, and J. Kopecek, Polymer conjugates with anticancer activity. Biopolymers Ii, 1995. 122: 55-123.
25. K. Ulbrich, and V. Subr, Polymeric anticancer drugs with pH-controlled activation. Adv. Drug Deliv. Rev., 2004. 56(7):1023-1050.
26. F. Kratz, U. Beyer, and M. T. Schutte, Drug-polymer conjugates containing acid-cleavable bonds. Crit. Rev. Ther. Drug Carrier Syst., 1999. 16(3): 245-288.
27. Rodrigues, P. C. A., et al., Correlation of the acid-sensitivity of polyethylene glycol daunorubicin conjugates with their in vitro antiproliferative activity. Bioorg. Med. Chem., 2006. 14(12): 4110-4117.
28. Meng, F. H., W. E. Hennink, and Z. Zhong, Reduction-sensitive polymers and bioconjugates for biomedical applications. Biomaterials, 2009. 30(12): 2180-2198.
29. Kopeček, J., et al., Synthetic Polymeric Drugs, U.S.P. 5, Editor. 1991.
30. E. Segal, et al., Enhanced anti-tumor activity and safety profile of targeted nano-scaled HPMA copolymer-alendronate-TNP-470 conjugate in the treatment of bone malignances. Biomaterials, 2011. 32(19): 4450-63.
31. E. Segal, et al., Targeting angiogenesis-dependent calcified neoplasms using combined polymer therapeutics. PLoS One, 2009. 4(4): e5233.
32. K. Miller, et al., Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugate. Angew. Chem. Int. Ed Engl., 2009. 48(16): 2949-54.
33. G. M. Dubowchik, et al., Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. Bioconjug. Chem., 2002. 13(4): 855-69.
34. C. Liu, et al., Overexpression of legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy. Cancer Res., 2003. 63(11):. 2957-64.
35. L. Stern, et al., A novel antitumor prodrug platform designed to be cleaved by the endoprotease legumain. Bioconjug. Chem., 2009. 20(3): 500-10.
36. F. Kratz, et al., Development and in vitro efficacy of novel MMP2 and MMP9 specific doxorubicin albumin conjugates. Bioorg. Med. Chem. Lett., 2001. 11(15): 2001-6.
37. F. Kratz, et al., Prodrug strategies in anticancer chemotherapy. ChemMedChem, 2008. 3(1): 20-53.
38. B. Apostolovic, et al., Hybrid polymer therapeutics incorporating bioresponsive, coiled coil peptide linkers. Biomacromolecules, 2010. 11(5): 1187-95.
39. L. W. Seymour, et al., Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J. Clin. Oncol., 2002. 20(6): 1668-76.
40. R. Vercauteren, E. Schacht, and R. Duncan, Effect of the Chemical Modification of Dextran on the Degradation by Rat Liver Lysosomal Enzymes. Journal of Bioactive and Compatible Polymers, 1992. 7(4): 346-357.
41. E. Auzenne, et al., Superior therapeutic profile of poly-L-glutamic acid-paclitaxel copolymer compared with taxol in xenogeneic compartmental models of human ovarian carcinoma. Clin. Cancer Res., 2002. 8(2): 573-81.
42. B. Crielaard, et al., Interaction of liposomes with proteins measured by surface plasmon resonance correlates with their in vivo circulation time. J. Control. Release, 2010. 148(1): e32-3.
43. L. Paz-Ares, et al., Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. Br. J. Cancer, 2008. 98(10): 1608-13.
44. M. E. O'Brien, et al., Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. J. Thorac. Oncol., 2008. 3(7): 728-34.
45. C. J. Langer, et al., Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. J. Thorac. Oncol., 2008. 3(6): 623-30.
46. N. J. Wheate, et al., The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans., 2010. 39(35): 8113-8127.
47. J. M. Rademaker-Lakhai, et al., A phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors. Clin. Cancer Res., 2004. 10(10): 3386-3395.
48. D. P. Nowotnik, and E. Cvitkovic, ProLindac (TM) (AP5346): A review of the development of an HPMA DACH platinum Polymer Therapeutic. Adv. Drug Deliv. Rev., 2009. 61(13): 1214-1219.
49. A. V. Yurkovetskiy, and R. J. Fram, XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancer. Adv. Drug Deliv. Rev., 2009. 61(13): 1193-1202.
50. J. J. Cheng, et al., Synthesis of linear, beta-cyclodextrin-based polymers and their camptothecin conjugates. Bioconjug. Chem., 2003. 14(5): 1007-1017.
51. M. E. Davis, Design and development of IT-101, a cyclodextrin-containing polymer conjugate of camptothecin. Adv. Drug Deliv. Rev., 2009. 61(13): 1189-1192.
52. R. Satchi-Fainaro, Targeting tumor vasculature: reality or a dream? J. Drug Target., 2002. 10(7): 529-33.
53. J. Folkman, and R. Kalluri, Tumor angiogenesis, in Cancer Medicine, Ed.: D.W. Kufe, et al., B.C. Decker Inc.: Hamilton, Ontario, Canada. 161-1942003.
54. J. Folkman, Angiogenesis: an organizing principle for drug discovery? Nat. Rev. Drug Discov., 2007. 6(4): 273-86.
55. D.M. McDonald, Angiogenesis and vascular remodeling in inflammation and cancer: biology and architecture of the vasculature, in angiogenesis: An Integrative Approach from Science to Medicine(Ed.: W.D. Figg and J. Folkman ), 2008, Springer: New York, New York, USA. 17-35.
56. T. Matsumoto, and L. Claesson-Welsh, VEGF receptor signal transduction. Sci. STKE, 2001. 2001(112): re21.
57. G. Neufeld, et al., Vascular endothelial growth factor (VEGF) and its receptors. FASEB J., 1999. 13(1): 9-22.
58. Folkman, J., Tumor angiogenesis: therapeutic implications. N. Engl. J. Med., 1971. 285(21): 1182-6.
59. N. Ferrara, and R. S. Kerbel, Angiogenesis as a therapeutic target. Nature, 2005. 438(7070): 967-74.
60. Germano, S. and L. O'Driscoll, Breast cancer: understanding sensitivity and resistance to chemotherapy and targeted therapies to aid in personalised medicine. Curr. Cancer Drug Targets, 2009. 9(3): 398-418.
61. F. Pastorino, et al., Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res., 2003. 63(21): 7400-9.
62. B. Stordal, N. Pavlakis, and R. Davey, A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship. Cancer Treat. Rev., 2007. 33(8): 688-703.
63. T. Browder, et al., Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res., 2000. 60(7): 1878-86.
64. G. Klement, et al., Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest., 2000. 105(8): R15-24.
65. L. Hlatky, P. Hahnfeldt, and J. Folkman, Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J. Natl. Cancer Inst., 2002. 94(12): 883-93.
66. M. Funovics, et al., Nanoparticles for the optical imaging of tumor E-selectin. Neoplasia, 2005. 7(10): 904-11.
67. L. A. Landon, and S.L. Deutscher, Combinatorial discovery of tumor targeting peptides using phage display. J. Cell. Biochem., 2003. 90(3): 509-17.
68. E. Ruoslahti, Drug targeting to specific vascular sites. Drug Discov. Today, 2002. 7(22): 1138-43.
69. E. Ruoslahti, and D. Rajotte, An address system in the vasculature of normal tissues and tumors. Annu. Rev. Immunol., 2000. 18: 813-27.
70. M. D. Pierschbacher and E. Ruoslahti, Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature, 1984. 309(5963): 30-3.
71. S. Liu, Radiolabeled cyclic RGD peptides as integrin alpha(v)beta(3)-targeted radiotracers: maximizing binding affinity via bivalency. Bioconjug. Chem., 2009. 20(12): 2199-213.
72. J. M. Bergelson, et al., Identification of the integrin VLA-2 as a receptor for echovirus 1. Science, 1992. 255(5052): 1718-20.
73. Leininger, E., et al., Pertactin, an Arg-Gly-Asp-containing Bordetella pertussis surface protein that promotes adherence of mammalian cells. Proc. Natl. Acad. Sci. U.S.A., 1991. 88(2): 345-9.
74. M. D. Pierschbacher and E. Ruoslahti, Influence of stereochemistry of the sequence Arg-Gly-Asp-Xaa on binding specificity in cell adhesion. J. Biol. Chem., 1987. 262(36): 17294-8.
75. S. L. Goodman, et al., Nanomolar small molecule inhibitors for alphav(beta)6, alphav(beta)5, and alphav(beta)3 integrins. J. Med. Chem., 2002. 45(5): 1045-51.
76. S. J. Bogdanowich-Knipp, et al., Solution stability of linear vs. cyclic RGD peptides. J. Pept. Res., 1999. 53(5): 530-41.
77. M. A. Dechantsreiter, et al., N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. J. Med. Chem., 1999. 42(16): 3033-40.
78. M. Aumailley et al., Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS Lett., 1991. 291(1): 50-4.
79. M. Paolillo, et al., Small molecule integrin antagonists in cancer therapy. Mini Rev. Med. Chem., 2009. 9(12): 1439-46.
80. NIH. http://clinicaltrials.gov/search/intervention=Cilengitide.
81. J. S. Desgrosellier, and D. A. Cheresh, Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer, 2010. 10(1): 9-22.
82. A. R. Reynolds, et al., Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat. Med., 2009. 15(4): 392-400.
83. G. C. Alghisi, L. Ponsonnet, and C. Ruegg, The integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells. PLoS One, 2009. 4(2): e4449.
84. W. Arap, R. Pasqualini, and E. Ruoslahti, Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science, 1998. 279(5349): 377-80.
85. J. W. Kim, and H. S. Lee, Tumor targeting by doxorubicin-RGD-4C peptide conjugate in an orthotopic mouse hepatoma model. Int. J. Mol. Med., 2004. 14(4): 529-35.
86. M. L. Janssen, et al., Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. Cancer Res., 2002. 62(21): 6146-51.
87. M. Janssen, et al., Improved tumor targeting of radiolabeled RGD peptides using rapid dose fractionation. Cancer Biother. Radiopharm., 2004. 19(4): 399-404.
88. H. J. Wester, and H. Kessler, Molecular targeting with peptides or peptide-polymer conjugates: just a question of size? J. Nucl. Med., 2005. 46(12): 1940-5.
89. L. Sancey, et al., Clustering and internalization of integrin alphavbeta3 with a tetrameric RGD-synthetic peptide. Mol. Ther., 2009. 17(5): 837-43.
90. M. P. Borgman, et al., Targetable HPMA copolymer-aminohexylgeldanamycin conjugates for prostate cancer therapy. Pharm. Res., 2009. 26(6): 1407-18.
91. J. M. Holzbeierlein A. Windsperger, and G. Vielhauer, Hsp90: a drug target? Curr. Oncol. Rep., 2010. 12(2): 95-101.
92. J. B. Lattouf, et al., Mechanisms of disease: the role of heat-shock protein 90 in genitourinary malignancy. Nat. Clin. Pract. Urol., 2006. 3(11): 590-601.
93. Y. Kasuya, et al., Influence of the structure of drug moieties on the in vitro efficacy of HPMA copolymer-geldanamycin derivative conjugates. Pharm. Res., 2002. 19(2): 115-23.
94. Kaur, G., et al., Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator. Clin. Cancer Res., 2004. 10(14): 4813-21.
95. C. Ryppa, et al., In vitro and in vivo evaluation of a paclitaxel conjugate with the divalent peptide E-[c(RGDfK)2] that targets integrin alpha v beta 3. Int. J. Pharm., 2009. 368(1-2): 89-97.
96. A. Eldar-Boock, et al., Integrin-assisted drug delivery of nano-scaled polymer therapeutics bearing paclitaxel. Biomaterials, 2011. 32(15): 3862-74.
97. D. Willner, et al., (6-Maleimidocaproyl)hydrazone of doxorubicin-a new derivative for the preparation of immunoconjugates of doxorubicin. Bioconjug. Chem., 1993. 4(6): 521-7.
98. 2] conjugate for integrin-targeted cancer therapy. Polymers for Advanced Technologies, 2011. 22(1):103-113.
99. L. Aagaard, and J. J. Rossi, RNAi therapeutics: principles, prospects and challenges. Adv. Drug Deliv. Rev., 2007. 59(2-3): 75-86.
100. P. Ofek, et al., In vivo delivery of small interfering RNA to tumors and their vasculature by novel dendritic nanocarriers. FASEB J., 2010. 24(9): 3122-34.
101. T. L. Kaneshiro, and Z.R. Lu, Targeted intracellular codelivery of chemotherapeutics and nucleic acid with a well-defined dendrimer-based nanoglobular carrier. Biomaterials, 2009. 30(29): 5660-6.
102. X. B. Xiong, et al., The therapeutic response to multifunctional polymeric nano-conjugates in the targeted cellular and subcellular delivery of doxorubicin. Biomaterials. 31(4): 757-68.
103. Bertozzi, C. R., Cracking the carbohydrate code for selectin recognition. Chem. Biol., 1995. 2(11): 703-8.
104. S. D. Rosen, and C. R. Bertozzi, The selectins and their ligands. Curr. Opin. Cell Biol., 1994. 6(5): 663-73.
105. S. R. Barthel, et al., Targeting selectins and selectin ligands in inflammation and cancer. Expert Opin. Ther. Targets, 2007. 11(11): 1473-91.
106. McEver, R. P., Selectin-carbohydrate interactions during inflammation and metastasis. Glycoconj. J., 1997. 14(5): 585-91.
107. H. Kobayashi, K. C. Boelte, and P. C. Lin, Endothelial cell adhesion molecules and cancer progression. Curr. Med. Chem., 2007. 14(4): 377-86.
108. Kannagi, R., et al., Carbohydrate-mediated cell adhesion in cancer metastasis and angiogenesis. Cancer Sci., 2004. 95(5): 377-84.
109. Laferriere, J., F. Houle, and J. Huot, Regulation of the metastatic process by E-selectin and stress-activated protein kinase-2/p38. Ann. N. Y. Acad. Sci., 2002. 973: 562-72.
110. C. Ehrhardt, C. Kneuer, and U. Bakowsky, Selectins-an emerging target for drug delivery. Adv. Drug Deliv. Rev., 2004. 56(4): 527-49.
111. Martens, C. L., et al., Peptides which bind to E-selectin and block neutrophil adhesion. J. Biol. Chem., 1995. 270(36): 21129-36.
112. Shamay, Y., et al., E-selectin binding peptide-polymer-drug conjugates and their selective cytotoxicity against vascular endothelial cells. Biomaterials, 2009. 30(32): 6460-8.
113. B. Rihova, Receptor-mediated targeted drug or toxin delivery. Adv. Drug Deliv. Rev., 1998. 29(3): 273-289.
114. Y. Shamay, et al., Multivalent display of quinic acid based ligands for targeting E-selectin expressing cells. J. Med. Chem., 2009. 52(19): 5906-15.
115. Luan, Y. and W. Xu, The structure and main functions of aminopeptidase N. Curr. Med. Chem., 2007. 14(6): 639-47.
116. S. V. Bhagwat, et al., CD13/APN is activated by angiogenic signals and is essential for capillary tube formation. Blood, 2001. 97(3): 652-9.
117. N. Petrovic, et al., CD13/APN regulates endothelial invasion and filopodia formation. Blood, 2007. 110(1): 142-50.
118. R. Pasqualini, et al., Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res., 2000. 60(3): 722-7.
119. X. Wang, et al., Activity screening and structure-activity relationship of the hit compounds targeting APN/CD13. Fundam Clin Pharmacol, 2010.
120. F. Curnis, et al., Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res., 2002. 62(3): 867-74.
121. L. Adar et al., Pro-apoptotic Peptide-Polymer Conjugates to Induce Mitochondrial-Dependent Cell Death. Polymers for Advanced Technologies, 2011. 22(1): 199-208.
122. L. L. Kiessling and N. L. Pohl, Strength in numbers: non-natural polyvalent carbohydrate derivatives. Chem. Biol., 1996. 3(2): 71-7.
123. R. Roy, Syntheses and some applications of chemically defined multivalent glycoconjugates. Curr. Opin. Struct. Biol., 1996. 6(5): 692-702.
124. Ellerby, H. M., et al., Anti-cancer activity of targeted pro-apoptotic peptides. Nat. Med., 1999. 5(9): 1032-8.
125. B. Law, et al., A mitochondrial targeted fusion peptide exhibits remarkable cytotoxicity. Mol. Cancer Ther., 2006. 5(8): 1944-9.
126. J. C. Mai, et al., A proapoptotic peptide for the treatment of solid tumors. Cancer Res., 2001. 61(21): 7709-12.
127. Javadpour, M. M., et al., De novo antimicrobial peptides with low mammalian cell toxicity. J. Med. Chem., 1996. 39(16): 3107-13.
128. D. C. Wallace, Mitochondria and cancer: Warburg addressed. Cold Spring Harb. Symp. Quant. Biol., 2005. 70: 363-74.
129. T. Etrych et al., New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: synthesis and preliminary in vitro and in vivo biological properties. J. Control. Release, 2001. 73(1): 89-102.
130. C. M. Isacke and H. Yarwood, The hyaluronan receptor, CD44. Int. J. Biochem. Cell Biol., 2002. 34(7): 718-21.
131. J. Bajorath et al., Identification of CD44 residues important for hyaluronan binding and delineation of the binding site. J. Biol. Chem., 1998. 273(1): 338-43.
132. A. David, Carbohydrate-Based Biomedical Copolymers for Targeted Delivery of Anticancer Drugs. Israel journal of Chemistry, 2010. 50.
133. G. Journo-Gershfeld, et al., Hyaluronan oligomers-HPMA copolymer conjugates for targeting paclitaxel to CD44-overexpressing ovarian carcinoma. Pharm. Res., 2012. 29(4): 1121-33.
134. B. Urban-Klein, et al., RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther., 2005. 12(5): 461-6.
135. D. Jere, et al., Degradable polyethylenimines as DNA and small interfering RNA carriers. Expert Opin. Drug Deliv., 2009. 6(8): 827-34.
136. Y. S. Choi, et al., The systemic delivery of siRNAs by a cell penetrating peptide, low molecular weight protamine. Biomaterials, 2010. 31(6): 1429-43.
137. K. Park, et al., Target specific tumor treatment by VEGF siRNA complexed with reducible polyethyleneimine-hyaluronic acid conjugate. Biomaterials, 2010. 31(19): 5258-5265.
138. G. Pasut, and F. M. Veronese, PEG conjugates in clinical development or use as anticancer agents: an overview. Adv. Drug Deliv. Rev., 2009. 61(13): 1177-88.
139. L. Chun, Poly(L-glutamic acid)-anticancer drug conjugates. Adv. Drug Deliv. Rev., 2002. 54: 695-713.
140. S. Bisht, and A. Maitra, Dextran-doxorubicin/chitosan nanoparticles for solid tumor therapy. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 2009. 1(4): 415-25.
141. A. D. Baldwin, and K. L. Kiick, Polysaccharide-modified synthetic polymeric biomaterials. Biopolymers, 2010. 94(1): 128-40.
142. M. Grzelinski, et al., RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Hum. Gene Ther., 2006. 17(7): 751-766.
143. D. B. Pike, and H. Ghandehari, HPMA copolymer-cyclic RGD conjugates for tumor targeting. Adv. Drug Deliv. Rev. 62(2) 167-83.